Key market opportunities include rising demand for bioanalytical testing due to increased drug development, prevalence of ...

Researchers at the University of Plymouth are leading an innovative initiative to advance the study of meningiomas in NF2-related schwannomatosis (NF2-SWN). Meningiomas, often linked to the loss of ...

Learn how AI is transforming predictions of drug-induced liver injury and aiding drug development for safer therapeutics.

MED Institute, a leader in pre-clinical and clinical medical product development services, is proud to announce a strategic collaboration with Sus Clinicals, a pioneering provider of genetic-modified ...

– New Data Suggests that IMU-856 Could Be a Potential Oral Treatment Option for Weight Management; Program Is Phase 2 Ready – – Dose-Dependent Increase of Endogenous GLP-1 Levels Observed in Post Hoc ...

NAMSA has acquired select assets of Labcorp’s early development medical device testing business, aligning with .

Approximately 75% of anticancer drugs must be tested against paediatric cancer. Drug developers can now use a database of patient-derived tumour models to screen their products for paediatric cancer ...

Plasma phosphorylated (p)-tau217 testing can help identify preclinical Alzheimer's disease (AD), which could aid clinical trial recruitment. Recruiting preclinical AD participants for clinical ...

HOUSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (BPTH),, a biotechnology company leveraging its proprietary DNAbilize ® liposomal delivery and antisense technology to develop a ...

Kymera Therapeutics has announced that Sanofi will advance their next-generation oral IRAK4 degrader, KT-485, into clinical testing, while opting not to pursue KT-474. Preclinical studies indicated ...

Modeling and simulation will be a key component for shift to non-animal methodologies Introducing NAMVantage(TM), a flagship package offering PBPK and QSP professional services and regulatory strategy ...